March 23, 2021 - Cambridge, MA The Sumaira Foundation for NMO (TSF) and Portal Instruments are pleased to announce their partnership. Portal Instruments and TSF share a joint vision of creating a better experience and improved treatment options for patients diagnosed with NMOSD.
March 23, 2021, Cambridge, MA The Sumaira Foundation for NMO (TSF) and Portal Instruments are pleased to announce their partnership.
Portal Instruments and TSF share a joint vision of creating a better experience and improved treatment options for patients diagnosed with neuromyelitis optica spectrum disorder.
Established in 2014, The Sumaira Foundation for NMO (TSF) is a 501(c)(3) organization founded and led by an NMO patient that is dedicated to generating global awareness of neuromyelitis optica spectrum disorder (NMOSD), fundraising to help find a cure, and creating a community of support for patients + their caregivers.
Portal Instruments is developing and commercializing a highly innovative needle-free jet injection platform that transforms the drug delivery experience for patients suffering from chronic disease. Portal’s aim is to replace all needles and syringes with a safe, fast, and connected device and empower the patient to holistically manage their chronic condition.
Barbara Taylor, VP of Commercial and Marketing at Portal Instruments said “Portal Instruments is thrilled to be working with The Sumaira Foundation as we share a vision of supporting and empowering patients. Portal sees the need to offer a needle-free solution to NMO patients and we are excited to be working with TSF and the NMO community to make this happen”
Elated about the partnership, Sumaira Ahmed, TSF Founder and Executive Director, adds, “As a patient who is not particularly eager to be ‘hooked up to an infusion pole’ as frequently as our treatment plans often require, I am eager to introduce the Portal device to our patient population. I genuinely believe that Portal’s innovative drug delivery method will afford our community with a semblance of independence – something many of us feel we lost after getting diagnosed with NMOSD.”
November 21, 2023 - Patrick Anquetil, CEO of Portal Instruments, takes the stage at LSI's 2023 Emerging MedTech Summit in Dana Point, California. Tune in to the recorded session to hear Dr. Anquetil dive into the innovative world of of needle-free and Portal's groundbreaking needle-free technology.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
October 2024 - At the Partnership Opportunities in Drug Delivery (PODD) conference, Robert Hidalgo showcased Portal Instrument's latest advancements on its reusable, electro-mechanical drug delivery platform.
Please fill out the details below and we will get back to you shortly.